Advertisement
LLY vs PFE
Which Stock Would AI Choose? Eli Lilly (LLY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- LLY has surged to record highs in recent weeks, driven by robust demand for its GLP-1 (glucagon-like peptide-1) obesity and diabetes medicines, with shares up roughly 21% year to date.
- PFE has also rallied, gaining roughly 18–25% in 2026, but its relative performance remains far more modest over a multi-year horizon.
- The two stocks represent contrasting profiles: LLY offers high-multiple growth momentum, while PFE offers a near-6% dividend yield and a lower forward valuation.
- PFE faces a significant patent cliff across key franchises, whereas LLY is expanding manufacturing capacity to meet growing demand for its incretin portfolio.
- Analyst sentiment is more uniformly bullish on LLY, while PFE garners a more mixed mix of Buy and Hold ratings.
- For more on each name, explore LLY Major News and LLY Today's Price Move, as well as PFE Major News and PFE Today's Price Move.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Introduction
Eli Lilly and Company (LLY) and Pfizer Inc. (PFE) are two of the largest names in global pharmaceuticals, yet they currently sit at opposite ends of the sector's growth spectrum. Lilly is riding a wave of demand for its cardiometabolic franchise, while Pfizer is repositioning after a post-pandemic revenue reset. This stock comparison is relevant to growth-oriented investors evaluating Lilly's momentum against income-focused investors weighing Pfizer's dividend and valuation. Traders monitoring sector rotation into healthcare may also find the relative performance and market positioning of these two bellwethers instructive.
LLY Overview and Recent Performance
Eli Lilly has emerged as one of the market's most prominent growth stories, with a market capitalization exceeding $1 trillion. Its performance has been anchored by incretin therapies—Mounjaro for type 2 diabetes, Zepbound for obesity, and the oral treatment Foundayo—that continue to capture market share. In recent weeks, LLY shares printed a fresh all-time high, with analysts attributing the strength to accelerating revenue growth, widening patient access through programs such as Medicare's GLP-1 bridge, and ongoing manufacturing expansion. Management has raised its full-year revenue outlook to roughly $86 billion. Wall Street sentiment is broadly constructive, with several firms lifting price targets and a consensus rating near "Strong Buy" heading into the company's next quarterly report.
PFE Overview and Recent Performance
Pfizer operates a diversified portfolio spanning primary care, specialty care, and oncology, with a substantial vaccine franchise. Following a sharp pullback from pandemic-era highs, PFE has rebuilt momentum in 2026, with shares up roughly 18–25% year to date—on track for its best annual performance since 2021. The stock has benefited from a broader rotation into higher-yielding, defensive healthcare names. Pfizer's forward dividend yield of roughly 5.8% ranks among the highest in the S&P 500, supported by a 352-quarter consecutive dividend history. However, the company is navigating a patent cliff across products including Eliquis, Xeljanz, Ibrance, and Xtandi, and analysts' ratings remain split between Buy and Hold as it works to replenish its pipeline.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated hub that surfaces the platform's most relevant AI trading bots for current market conditions. Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but only a select group is featured here. These robots differ in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, allowing users to evaluate approaches ranging from short-term momentum to longer-horizon trend strategies. The curated list is designed to help traders identify tools that align with prevailing market dynamics. Explore the Trending AI Robots page to review the currently featured strategies.
Head-to-Head Comparison
The core contrast between these two names is growth versus income. LLY commands a premium valuation—its trailing price-to-earnings (P/E) ratio sits in the mid-40s—reflecting expectations for sustained double-digit sales growth from its incretin franchise and a comparatively low dividend yield near 0.5%. PFE trades near a forward P/E of roughly 10 and offers a dividend yield around 5.8%, positioning it as a value and income candidate rather than a growth engine. Risk profiles also differ: Pfizer's principal challenge is replacing revenue from medicines losing exclusivity, while Lilly's main considerations include competitive intensity in obesity from rivals such as Novo Nordisk and the execution of large-scale manufacturing investments. On market sentiment, Lilly enjoys a more consistent uptrend and firmer analyst consensus, whereas Pfizer's momentum is newer and more dependent on pipeline delivery and successful cost restructuring.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely favor LLY in the current environment. The stock's sustained uptrend, record-high price action, broadening patient access, and positive earnings revisions suggest stronger momentum and more clearly defined near-term catalysts. PFE presents a more probabilistic turnaround thesis tied to pipeline execution and patent-cliff navigation, which introduces greater uncertainty despite an attractive dividend. This assessment reflects relative trend strength and positioning rather than a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Hold and PFE is a Buy.
LLY in upward trend: 10-day moving average moved above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 233 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.296) is slightly higher than the industry average of (-1.376). P/E Ratio (47.489) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.039) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
PFE in +3.63% Uptrend, advancing for three consecutive days on October 30, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 37 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 43%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 21 of 42 cases over the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 13 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.042) is normal, around the industry mean (-1.376). P/E Ratio (39.636) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.056) settles around the average of (0.039) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
LLY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 94 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 100 | |
SMR RATING 1..100 | 14 | 83 | |
PRICE GROWTH RATING 1..100 | 4 | 20 | |
P/E GROWTH RATING 1..100 | 26 | 3 | |
SEASONALITY SCORE 1..100 | 25 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LLY's Valuation (88) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that LLY’s stock grew similarly to PFE’s over the last 12 months.
LLY's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (83). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
LLY's Price Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as PFE (20). This means that LLY’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as LLY (26). This means that PFE’s stock grew similarly to LLY’s over the last 12 months.
| LLY | PFE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 56% | 3 days ago 50% |
| Stochastic ODDS (%) | 3 days ago 52% | 3 days ago 57% |
| Momentum ODDS (%) | 3 days ago 62% | 3 days ago 43% |
| MACD ODDS (%) | 3 days ago 82% | 3 days ago 50% |
| TrendWeek ODDS (%) | 3 days ago 70% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 49% |
| Advances ODDS (%) | 3 days ago 70% | 3 days ago 54% |
| Declines ODDS (%) | about 1 month ago 55% | 7 days ago 56% |
| BollingerBands ODDS (%) | 3 days ago 47% | 6 days ago 50% |
| Aroon ODDS (%) | 3 days ago 78% | 3 days ago 65% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 4 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- LLY’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- LLY’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а +11.31% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.63% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.16%. For the same industry, the average monthly price growth was -2.39%, and the average quarterly price growth was +4.91%.
Reported Earning Dates
LLY is expected to report earnings on Feb 10, 2027.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.